Partners Roche and Exelixis are making their case to regulators with a melanoma-treating combination therapy, filing an FDA application for the fast-tracked treatment as they await European clearance.
Having shepherded Genentech's R&D operations through the takeover by Roche, Richard Scheller will retire at the end of 2014. Roche has lined up Michael Varney, Genentech's head of small molecule drug discovery, to replace Scheller.
Roche snatched up AvanSci Bio's tissue dissection technology for the analysis of tumors, diversifying its product offerings and continuing its molecular diagnostics push.
The flu season's most common viral strain has mutated, meaning this year's shots may not fully protect against it. But the so-called "drifted" strain may open up an opportunity for antiviral makers like Roche's Genentech and GlaxoSmithKline, with the CDC urging earlier use of anti-flu drugs to combat potentially severe symptoms.
How did Genentech persuade physicians to switch from $50-a-dose Avastin to $2000-a-dose Lucentis? According to The New York Times, consultation payments may have had something to do with it.
An Italian regional court is upholding charges levied earlier this year against Roche and Novartis, fining the companies €180 million for manipulating sales of Lucentis, their drug for wet age-related macular degeneration.
Roche has been on a diagnostics roll as of late, pushing for regulatory approval of proprietary technology and striking deals to gain a stronger foothold in emerging markets. Now, the Swiss drugmaker is entering the prenatal diagnostics space with its purchase of Ariosa Diagnostics.
Roche is diving into the prenatal testing business, snatching up Ariosa Diagnostics to expand its diagnostics offerings and to get its hands on the company's noninvasive prenatal test for genetic abnormalities.
Months after the U.K.'s drug price watchdog the National Institute for Health and Care Excellence gave a preliminary thumbs-down to Roche's Gazyvaro for chronic lymphocytic leukemia, the agency is now set to recommend the drug in new draft guidance with a few strings attached.
Targeted drugs, personalized medicine, stratified therapy--whatever you call it, using biomarkers to identify particular patients for particular drugs has been hailed as a boon for patients and a savvy strategy for pharma.